The trial is taking place at:
F

Fort Bend Clinical Research | Sugar Land , TX

Veeva-enabled site

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

Roche logo

Roche

Status and phase

Active, not recruiting
Phase 3

Conditions

Lupus Nephritis

Treatments

Drug: Obinutuzumab
Drug: MMF
Drug: Prednisone
Drug: Methylprednisolone
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04221477
2019-004034-42 (EudraCT Number)
2023-503628-22-00 (Other Identifier)
CA41705

Details and patient eligibility

About

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.

Enrollment

252 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Diagnosis of active or active/chronic ISN/RPS 2003 Class III or IV proliferative LN as evidenced by renal biopsy performed within 6 months. Participants may co-exhibit Class V disease in addition to either Class III or Class IV disease
  • Urine protein to creatinine ratio greater than or equal to (>/=) 1 on a 24-hour collection
  • Other inclusion criteria may apply

Key Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Severe renal impairment or the need for dialysis or renal transplantation
  • Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
  • Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation
  • Known active infection of any kind or recent major episode of infection
  • Intolerance or contraindication to study therapies
  • Other exclusion criteria may apply

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

252 participants in 2 patient groups, including a placebo group

Obinutuzumab
Experimental group
Description:
Participants will be randomized into 2 groups. Group 1 will receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Group 2 receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, and 52 plus MMF and oral prednisone. Group 2 participants will receive a placebo infusion at their Week 50 visit. Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80. Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80.
Treatment:
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: Methylprednisolone
Drug: Prednisone
Drug: MMF
Drug: Obinutuzumab
Placebo
Placebo Comparator group
Description:
Placebo participants will receive obinutuzumab matched placebo at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80. Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80.
Treatment:
Drug: Placebo
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: Methylprednisolone
Drug: Prednisone
Drug: MMF
Drug: Obinutuzumab

Trial contacts and locations

83

Loading...

Central trial contact

Reference Study ID Number: CA41705 https://forpatients.roche.com/

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems